Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells

Gene Therapy

Volumn 21, Issue 3, 2014, Pages 262-271

  Pen, J J ^a   Keersmaecker, B D ^a   Heirman, C ^a   Corthals, J ^a   Liechtenstein, T ^b,c   Escors, D ^b,c   Thielemans, K ^a   Breckpot, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

CD4+ and CD8+ T cell; dendritic cell; multifunctional; PD 1 PD L1 pathway

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 12; LYMPHOCYTE ANTIGEN; MESSENGER RNA; NUCLEAR PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR LIGAND; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFIC T LYMPHOCYTE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOLOGICAL SYNAPSE; IMMUNOSTIMULATION; INFLUENZA VIRUS; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ORTHOMYXOVIRIDAE;

ANTIGEN PRESENTATION; ANTIGENS, CD80; B7 ANTIGENS; DENDRITIC CELLS; HEK293 CELLS; HUMANS; INTERLEUKIN-10; NUCLEOPROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS;

EID: 84908031412     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.80     Document Type: Article

References (60)

1. Wolfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, Netski D et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol 2008; 181: 6435-6446.
2. Zajac AJ, Murali-Krishna K, Blattman JN, Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4\+ and CD8\+ T cells. Curr Opin Immunol 1998; 10: 444-449. (Pubitemid 28393828)
3. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296. (Pubitemid 46697910)
4. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188: 2205-2213. (Pubitemid 29028493)
5. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846.
6. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH et al. Impaired effector function of hepatitis C virus-specific CD8\+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-3458. (Pubitemid 35013196)
7. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-685. (Pubitemid 29289432)
8. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
9. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553. (Pubitemid 46447020)
10. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008; 181: 8215-8225.
11. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
12. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. (Pubitemid 351600389)
13. Punkosdy GA, Blain M, Glass DD, Lozano MM, O'Mara L, Dudley JP et al. Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. Proc Natl Acad Sci USA 2011; 108: 3677-3682.
14. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4\+ CD25(Hi) regulatory T cells. Int Immunol 2009; 21: 1065-1077.
15. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8\+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005; 6: 280-286. (Pubitemid 41724765)
16. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
17. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111: 3635-3643.
18. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
19. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
20. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1: 1223-1225.
21. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354. (Pubitemid 44435155)
22. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4\+ T cell activation during HIV infection. Nat Med 2010; 16: 452-459.
23. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687. (Pubitemid 43237609)
24. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322. (Pubitemid 32096320)
25. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity 1999; 11: 141-151. (Pubitemid 29428807)
26. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(\+) T lymphocytes. Immunity 2004; 20: 327-336. (Pubitemid 38388234)
27. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666-669. (Pubitemid 35435182)
28. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56: 1513-1537. (Pubitemid 47094397)
29. Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 2011; 142: 252-268.
30. Karwacz K, Arce F, Bricogne C, Kochan G, Escors D. PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology 2012; 1: 86-88.
31. Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor downmodulation on CD8\+ T cells. EMBO Mol Med 2011; 3: 581-592.
32. Liechtenstein T, Dufait I, Lanna A, Breckpot K, Escors D. Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. Immunol Endocr Metab Agents Med Chem 2012; 12: 224-235.
33. Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4\+Foxp3\+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res 2012; 18: 1925-1935.
34. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A et al. Restoring immune function of tumor-specific CD4\+ T cells during recurrence of melanoma. J Immunol 2013; 190: 4899-4909.
35. Shen T, Zheng J, Liang H, Xu C, Chen X, Zhang T et al. Characteristics and PD-1 expression of peripheral CD4\+CD127loCD25hiFoxP3\+ Treg cells in chronic HCV infected-patients. Virol J 2011; 8: 279.
36. Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011; 60: 47-53.
37. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
38. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011; 350: 17-37.
39. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4\+CD25\+Foxp3\+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320-329. (Pubitemid 46033615)
40. Pen J, De Keersmaecker B, Maenhout S, Van Nuffel AMT, Heirman C, Corthals J et al. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol 2013; 191: 1976-1983.
41. Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011; 63: 84-95.
42. Escors D, Bricogne C, Arce F, Kochan G, Karwacz K. On the Mechanism of T cell receptor down-modulation and its physiological significance. J Biosci Med 2011; 1: 1-9.
43. Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol 2005; 235: 109-116. (Pubitemid 41597474)
44. He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin 2005; 26: 462-468. (Pubitemid 40477995)
45. Wan B, Nie H, Liu A, Feng G, He D, Xu R et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006; 177: 8844-8850. (Pubitemid 44893851)
46. Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 2012; 7: e35178.
47. Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8(\+) T-cell responses by soluble PD-1. J Immunother 2011; 34: 297-306.
48. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D et al. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004; 173: 4919-4928. (Pubitemid 39387773)
49. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4\+ T cell activation. Eur J Immunol 2006; 36: 2472-2482. (Pubitemid 44420603)
50. Cederbom L, Hall H, Ivars F. CD4\+CD25\+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538-1543. (Pubitemid 30342794)
51. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4\+CD25\+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172: 4676-4680. (Pubitemid 38456386)
52. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006; 203: 2223-2227. (Pubitemid 44498355)
53. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B et al. Upregulation of PD-1 expression on HIV-specific CD8\+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202. (Pubitemid 44527357)
54. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5: 654-667. (Pubitemid 40309704)
55. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010; 84: 5627-5636.
56. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264: 135-151. (Pubitemid 34615899)
57. Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72: 1661-1671.
58. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-6657. (Pubitemid 38669100)
59. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E et al. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-3142. (Pubitemid 28018007)
60. Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C et al. Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8\+ T cell response. J Leukoc Biol 2005; 78: 898-908. (Pubitemid 41384406)